

SMI, the industry leaders in respiratory events, presents the 7th annual conference...

COPD

Novel therapeutics and management strategies

19th & 20th Oct 2015 | Holiday Inn Regents Park Hotel, London UK

www.copd-conference.com/INDERSCIENCE

Sponsored by Quintiles

COPD causes 6% of the world's morbidity and costs the worldwide economy \$36 billion and though non curable, it can be tamed through a range of management mechanisms. SMI's 7th annual conference on COPD will bring together respiratory leaders and scientific pioneers to strengthen knowledge in combinational therapies, new drugs and personalised treatment, whilst keeping you at the forefront of scientific breakthroughs to adapt to the growing need for efficiency in the management of exacerbations.

Understanding COPD pulmonary indications through biomarkers and the practicalities of reliable clinical trials will be a major focus as will hearing from a selection of pharmaceutical organisations currently developing scientific trials for COPD. This will include case studies from Novartis, Mundipharma, Janssen, MedImmune and Bayer.

Exclusive updates into formulation developments and the manufacturing of dry powder inhalation products, lymphoid follicles in COPD and ACOS (Asthma, COPD, Overlap Syndrome) will be just some of the conference highlights this year.

Featured speakers Include:

- **Frank Thielmann**, Operational Lead, Inhalation New Solids, **Novartis Pharma AG**
- **Philip Silkoff**, Senior Medical Director, **Johnson and Johnson Pharmaceutical Services LLC**
- **Stefano Petruzzelli**, Chief Medical Officer and Director, Global Clinical Development, **Chiesi Farmaceutici S.p.A**
- **Sanjeeva Dissanayake**, Head of Medical Sciences – Respiratory, **Mundipharma**
- **Noel Snell**, Director of Research, **British Lung Foundation**
- **Geoff Down**, Chief Medical Officer, **Prosonix**
- **Konstantinos Kostikas**, Medical Director Respiratory COPD Region Europe, **Novartis Pharma**
- **Thomas Schlange**, Senior Biomarker Expert, **Bayer**
- **Matthew Sleeman**, Senior Director of Biology, Respiratory, Inflammation and Autoimmunity, **MedImmune**

Benefits of attending:

- Discuss the advantages and disadvantages of combinational therapeutics
- Gain insight into formulation developments and the manufacturing of dry powder inhalation products
- Evaluate COPD and comorbidities
- Review the challenges in clinical trial designs and in drug development
- Learn about "first in class" inhaled drugs for the treatment of COPD and cystic fibrosis
- Ascertain the ACOS Definition and characteristics of a grey-zone syndrome, excluded from current asthma and COPD trials
- Explore recent advances made in COPD biomarkers
- Study the role of lymphoid follicles in COPD Novel delivery and formulation methods

- Analyse airway disease endotyping for personalized therapeutics

For further details and to download a brochure, visit www.copd-conference.co.uk/INDERSCIENCE